Hyponatraemia — Sodium Correction Rate
Sex
دليل مفصل قريبًا
نعمل على إعداد دليل تعليمي شامل لـ Sodium Correction Rate (Hyponatraemia). عد قريبًا للاطلاع على الشروحات خطوة بخطوة والصيغ والأمثلة الواقعية ونصائح الخبراء.
Sodium correction rate is the calculated speed at which serum sodium concentration should be raised when treating hyponatraemia (serum sodium <135 mmol/L) or lowered when treating hypernatraemia (serum sodium >145 mmol/L). Hyponatraemia is the most common electrolyte disorder in hospitalised patients and carries significant morbidity and mortality if managed incorrectly. The rate of correction — critically — depends on whether hyponatraemia is acute or chronic. Acute symptomatic hyponatraemia (onset <48 hours) poses the risk of cerebral oedema and herniation, requiring rapid initial correction of 1–2 mmol/L per hour until neurological symptoms resolve, with a maximum bolus-based correction. Chronic hyponatraemia (onset ≥48 hours or unknown) carries the opposite risk: osmotic demyelination syndrome (ODS, formerly central pontine myelinolysis) when correction is too rapid, resulting in locked-in syndrome, quadriplegia, or death. The universally accepted safe limit for chronic hyponatraemia correction is ≤10–12 mmol/L per 24 hours, with some guideline recommendations of ≤8 mmol/L/24h in the highest-risk patients (alcoholism, malnutrition, severe hypokalaemia, liver disease). The primary treatment fluid for symptomatic hyponatraemia is 3% hypertonic saline (sodium concentration 513 mmol/L in the UK/Europe; similar in US). Understanding the rate of correction, volume required, and duration of infusion is essential for safe hyponatraemia management. Concurrent management of the underlying cause — SIADH, hypothyroidism, adrenal insufficiency, heart failure, cirrhosis — is mandatory alongside any correction strategy.
Sodium deficit (mmol) = TBW × (target Na − current Na); TBW = weight (kg) × 0.6 (males), 0.5 (females), 0.45 (elderly); Volume of 3% NaCl (mL) = sodium deficit ÷ 0.513; Safe correction limit: chronic hyponatraemia ≤10–12 mmol/L/24h; acute symptomatic: 1–2 mmol/L/h until resolution (max 8 mmol/L in any 4h); SIADH fluid restriction: <800 mL/day if urine osmolality >500 mOsm/kg
- 1Classify the hyponatraemia by duration and severity: acute (<48h onset) vs chronic (≥48h or unknown); severity by neurological symptoms — mild (nausea, malaise), moderate (confusion, headache), severe (seizures, respiratory arrest, coma, GCS ≤8).
- 2Determine the aetiology: measure urine sodium, urine osmolality, and serum osmolality; clinically assess volume status (hypovolaemic — diarrhoea/diuretics; euvolaemic — SIADH, hypothyroidism; hypervolaemic — heart failure, cirrhosis, nephrotic syndrome).
- 3Calculate the total body water (TBW): TBW = 0.6 × weight for males, 0.5 × weight for females, 0.45 × weight for elderly; use actual body weight for TBW calculation.
- 4Calculate the sodium deficit: Sodium deficit (mmol) = TBW × (target sodium − current sodium); target should be current sodium + 10 mmol/L for the first 24 hours (maximum correction limit), not the final target of 135 mmol/L.
- 5Calculate the 3% NaCl volume required: Volume (mL) = Sodium deficit ÷ 0.513 (since 3% NaCl contains 513 mmol/L Na); divide this volume by the number of hours to determine infusion rate in mL/h.
- 6For severe acute symptomatic hyponatraemia: give 3% NaCl 150 mL IV bolus over 20 minutes; repeat once or twice if symptoms persist; target Na rise of 4–6 mmol/L in the first hour — this alone often resolves cerebral oedema symptoms.
- 7Monitor serum sodium every 2–4 hours initially; if correction is proceeding faster than 10–12 mmol/L/24h, immediately reduce or stop hypertonic saline, administer 10 mL/kg of electrolyte-free water (5% dextrose) to re-lower sodium, and consider desmopressin (DDAVP) 2 mcg IV to clamp ongoing urinary losses — this 're-lowering' strategy prevents ODS.
Target Na 128 mmol/L (not 135) is the 24-hour goal; check Na every 2–4h and adjust infusion rate to not exceed 10 mmol/L/24h.
The infusion rate of 34 mL/h delivers the calculated sodium deficit over 24 hours; real-world correction often differs from calculated due to ongoing renal sodium handling — serial monitoring is essential.
In acute symptomatic hyponatraemia, the risk of cerebral herniation exceeds the risk of ODS; urgent correction is life-saving.
The 150 mL bolus of 3% NaCl (77 mmol Na) raises sodium approximately 2–4 mmol/L in a 55 kg woman; repeat boluses deliver further acute correction while neurological monitoring continues.
DDAVP 'clamps' the aquaporin channels and stops further free water excretion, allowing administered 5% dextrose to lower serum sodium.
Overcorrection is a medical emergency; re-lowering serum sodium to <130 mmol/L within the first 24 hours significantly reduces the risk of osmotic demyelination if acted upon promptly.
Chronic hypernatraemia should not be corrected faster than 10 mmol/L/24h — rapid correction causes cerebral oedema.
Just as rapid correction of hyponatraemia causes ODS, rapid correction of chronic hypernatraemia causes cerebral oedema by osmotic water shift into brain cells; gradual correction over 48–72h is safe.
ICU physicians calculate sodium correction rates daily for SIADH patients, adjusting 3% NaCl infusion rates based on serial sodium monitoring every 4–6 hours., where accurate sodium correction rate analysis through the Sodium Correction Rate supports evidence-based decision-making and quantitative rigor in professional workflows
Acute medicine teams use sodium correction calculators when admitting patients with symptomatic hyponatraemia from emergency departments, enabling target-driven infusion prescribing., where accurate sodium correction rate analysis through the Sodium Correction Rate supports evidence-based decision-making and quantitative rigor in professional workflows
Pharmacists review sodium correction prescriptions in hospitalised patients to ensure the prescribed 3% NaCl infusion rate does not exceed safe daily limits., where accurate sodium correction rate analysis through the Sodium Correction Rate supports evidence-based decision-making and quantitative rigor in professional workflows
Neurosurgery teams manage post-operative hyponatraemia after pituitary surgery, transsphenoidal procedures, and subarachnoid haemorrhage using SIADH vs cerebral salt wasting differentiation., where accurate sodium correction rate analysis through the Sodium Correction Rate supports evidence-based decision-making and quantitative rigor in professional workflows
General practitioners use free water deficit calculations to prescribe appropriate fluid types and rates for elderly patients with dehydration-related hypernatraemia in community and residential care settings.
Exercise-associated hyponatraemia (EAH)
EAH occurs in endurance athletes (marathons, triathlons) who consume excessive hypotonic fluids during exercise, diluting serum sodium. Serum sodium can fall to <120 mmol/L within hours. Acute cerebral oedema can develop rapidly. Treatment is 3% NaCl bolus (100–150 mL) regardless of duration because EAH is always acute. Isotonic fluid or drinking further water is contraindicated — it worsens dilutional hyponatraemia.
Post-operative hyponatraemia
Peri-operative hyponatraemia from excessive 5% dextrose or hypotonic maintenance fluid administration is acute and carries risk of cerebral oedema, particularly in menstruating women and children who are physiologically predisposed to cerebral swelling from hypo-osmolar stress. Rapid correction is appropriate when symptomatic; preventive strategy is use of isotonic balanced crystalloid for perioperative fluid administration.
Hyponatraemia with concurrent hypokalaemia
Potassium replacement in hypokalaemic patients paradoxically raises serum sodium (because potassium replaces intracellular sodium as the dominant cation, shifting sodium extracellularly). This 'hidden' correction must be factored into the total sodium correction budget; a patient receiving IV potassium replacement concurrently with hypertonic saline is at high risk of overcorrecting sodium too rapidly.
Psychogenic polydipsia
Psychiatric patients (especially those on antipsychotics) may develop profound dilutional hyponatraemia through compulsive water drinking. Because onset can be rapid (hours to days), correction can be more liberal than in typical chronic SIADH. However, distinguishing the timeline from chronic psychiatric-related SIADH is essential — many patients have overlapping mechanisms.
| Scenario | Correction Rate | Primary Treatment | Monitoring |
|---|---|---|---|
| Acute severe hyponatraemia (seizure/coma) | 1–2 mmol/L/h until symptoms resolve; max 8 mmol/L in 4h | 3% NaCl 150 mL bolus IV × 1–3 | Na every 1–2h; stop once symptoms resolve |
| Chronic hyponatraemia (moderate symptoms) | ≤8–10 mmol/L/24h | 3% NaCl infusion 15–30 mL/h | Na every 4–6h; adjust infusion rate |
| Chronic hyponatraemia (asymptomatic, SIADH) | ≤10–12 mmol/L/24h | Fluid restriction <800 mL/day; treat cause | Na every 6–12h |
| High-risk chronic hyponatraemia (alcohol, liver) | ≤6–8 mmol/L/24h | Careful isotonic fluids + treat cause | Na every 2–4h; DDAVP if overcorrection risk |
| Overcorrection detected | Re-lower to <130 mmol/L | 10 mL/kg 5% dextrose + DDAVP 2 mcg IV | Na every 2h until stable |
| Chronic hypernatraemia | ≤10 mmol/L/24h reduction | 5% dextrose or free water; treat cause | Na every 4–6h |
What is osmotic demyelination syndrome (ODS)?
ODS (formerly central pontine myelinolysis) is a devastating neurological complication caused by overcorrection of chronic hyponatraemia. It occurs when rapid sodium correction triggers osmotic fluid shifts that destroy the myelin sheaths of central pontine neurons. Clinical features appear 2–6 days after overcorrection and include: dysarthria, dysphagia, spastic quadriplegia, altered consciousness, and locked-in syndrome. ODS may be irreversible. Prevention — strict adherence to correction rate limits — is the only effective strategy.
What is the sodium concentration of 3% saline?
3% hypertonic saline (hypertonic NaCl) contains approximately 513 mmol/L of sodium (or 513 mEq/L). This compares to normal (0.9%) saline at 154 mmol/L and 0.45% saline at 77 mmol/L. The high sodium concentration of 3% saline makes small volumes effective at raising serum sodium; typical bolus doses of 100–150 mL can raise serum sodium by 1–3 mmol/L.
How does SIADH cause hyponatraemia?
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) causes hyponatraemia through continued secretion of ADH (antidiuretic hormone/vasopressin) despite low serum osmolality. ADH acts on renal V2 receptors to retain free water via aquaporin-2 channels, diluting serum sodium. SIADH is diagnosed by: hyponatraemia + urine osmolality >100 mOsm/kg + urine sodium >30 mmol/L in a euvolaemic patient with normal renal, adrenal, and thyroid function.
What is the maximum safe sodium correction rate?
For chronic hyponatraemia: ≤10–12 mmol/L per 24 hours. In high-risk patients (alcoholism, malnutrition, liver disease, severe hypokalaemia, potassium-depletion), the target should be ≤8 mmol/L per 24 hours. For acute symptomatic hyponatraemia, 1–2 mmol/L per hour until symptoms resolve is acceptable, but total correction should not exceed 10–12 mmol/L in 24h thereafter.
What is the difference between SIADH and cerebral salt wasting?
Both cause hyponatraemia in the context of brain injury, but through opposite mechanisms. SIADH: euvolaemia, high ADH, water retention — treatment is fluid restriction. Cerebral salt wasting (CSW): hypovolaemia, elevated natriuresis — the kidneys actively excrete sodium leading to volume depletion that stimulates ADH secondarily. Treatment for CSW is sodium and fluid replacement, not restriction. Correctly distinguishing them is critical because fluid restriction in CSW can worsen cerebral ischaemia.
What medications can cause SIADH?
Common drug causes of SIADH include: SSRIs (especially in elderly), SNRIs, carbamazepine, oxcarbazepine, cyclophosphamide, vincristine, NSAIDs, proton pump inhibitors, opioids, tricyclic antidepressants, and antipsychotics. Medication review is a critical step in all new hyponatraemia diagnoses. This is particularly important in the context of sodium correction rate calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise sodium correction rate computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
When is tolvaptan (a vasopressin receptor antagonist) used?
Tolvaptan (Samsca) blocks V2 renal vasopressin receptors, causing 'aquaresis' (free water excretion without sodium loss) and is licensed for euvolaemic and hypervolaemic hyponatraemia (SIADH, heart failure, cirrhosis). It is contraindicated in hypovolaemic hyponatraemia and must never be used for acute severe hyponatraemia. It carries a risk of ODS from overly rapid correction if not carefully monitored; hospitalisation is required for initiation.
How do I calculate the free water deficit in hypernatraemia?
Free Water Deficit (L) = TBW × [(serum Na / 140) − 1], where TBW = 0.6 × weight (males), 0.5 × weight (females/elderly). The deficit should be replaced with electrolyte-free water (5% dextrose or free water via NG tube) at a rate not exceeding 10 mmol/L sodium reduction per 24 hours. Ongoing insensible losses must also be replaced to prevent re-accumulation.
نصيحة احترافية
A practical safeguard against overcorrection in chronic hyponatraemia: after calculating the 24-hour dose of hypertonic saline, divide it into two 12-hour infusion bags. Check sodium at the end of each 12-hour bag. If correction of 6 mmol/L has been achieved in the first 12 hours, stop the second bag and switch to fluid restriction alone — this step-check approach virtually eliminates inadvertent overcorrection.
هل تعلم؟
The discovery of osmotic demyelination syndrome in the 1950s–1970s was initially attributed to a mysterious primary demyelinating disease. The crucial link to rapid sodium correction was not established until 1981, when Adams et al. described central pontine myelinolysis in alcoholic patients treated for hyponatraemia. This discovery fundamentally changed how electrolyte disorders were managed in ICUs worldwide.
المراجع
- ›Spasovski G et al. — Clinical practice guideline on diagnosis and treatment of hyponatraemia (ESE/ERA-EDTA 2014)
- ›Verbalis JG et al. — Diagnosis, evaluation, and treatment of hyponatraemia: Expert Panel Recommendations (Am J Med 2013)
- ›Sterns RH — Disorders of plasma sodium (NEJM 2015)
- ›NICE CKS — Hyponatraemia
- ›Hoorn EJ, Zietse R — Diagnosis and treatment of hyponatraemia: Compilation of evidence-based recommendations (Nephron 2017)